Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)

Frances M. Cole, George S. Laszlo, Margaret C. Lunn-Halbert, Allie R. Kehret, Patrick A. Zweidler-McKay, Eduardo Rodríguez-Arbolí, David Wu, Kyle E. Nyberg, Junyang Li, Sheryl Y. T. Lim, Sribalaji Lakshmikanthan, Roland B. Walter

Blood (2024) 144 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2024-200907

Published: 2024

Journal Articles

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Blood (2024) 143 (20): 2053–2058.

https://doi.org/10.1182/blood.2023021184

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study

Brent L. Wood, Meenakshi Devidas, Ryan J. Summers, Zhiguo Chen, Barbara Asselin, Karen R. Rabin, Patrick A. Zweidler-McKay, Naomi J. Winick, Michael J. Borowitz, William L. Carroll, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger, Kimberly P. Dunsmore, David T. Teachey, Stuart S. Winter

Blood (2023) 142 (24): 2069–2078.

https://doi.org/10.1182/blood.2023020678

Published: 2023

Includes: Supplemental data

Journal Articles

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

Anna Skwarska, Vinitha Mary Kuruvilla, Qi Zhang, Sovira Chaudhry, Naval Daver, Krystal Watkins, Callum Mortimer Sloss, Patrick A. Zweidler-McKay, Deepa Sampath, Marina Y. Konopleva

Blood (2023) 142 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2023-187018

Published: 2023

Journal Articles

Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model

Margaux Poussard, Morgane Boichut, Imane Belakri, Sabeha Biichle, Maxime Fredon, Florian Renosi, Francine Garnache Ottou, Krystal Watkins, Callum Mortimer Sloss, Patrick A. Zweidler-McKay, Fanny Delettre

Blood (2023) 142 (Supplement 1): 2791.

https://doi.org/10.1182/blood-2023-185602

Published: 2023

Journal Articles

Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children's Oncology Group (COG) Studies AALL0434 and AALL1231

Susan I. Colace, Meenakshi Devidas, Zhiguo (Bruce) Chen, Robert J. Hayashi, Brent L. Wood, Natia Esiashvili, Samir Patel, Andrew J Carroll, Nyla A. Heerema, Barbara Asselin, Karen R. Rabin, Patrick A. Zweidler-McKay, Elizabeth A. Raetz, Mignon L. Loh, Naomi J. Winick, William L. Carroll, David T. Teachey, Stuart S. Winter, Kimberly P. Dunsmore

Blood (2023) 142 (Supplement 1): 517.

https://doi.org/10.1182/blood-2023-190141

Published: 2023

Journal Articles

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report

Nathan P. Gossai, Meenakshi Devidas, Zhiguo Chen, Brent L. Wood, Patrick A. Zweidler-McKay, Karen R. Rabin, Mignon L. Loh, Elizabeth A. Raetz, Naomi J. Winick, Michael J. Burke, Andrew J. Carroll, Natia Esiashvili, Nyla A. Heerema, William L. Carroll, Stephen P. Hunger, Kimberly P. Dunsmore, Stuart S. Winter, David T. Teachey

Blood (2023) 141 (15): 1802–1811.

https://doi.org/10.1182/blood.2022018653

Published: 2023

Includes: Supplemental data

Journal Articles

Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Richard B Lock, Kathryn Evans, Joanna Randall, Stephen W Erickson, Eric J Earley, Steven Neuhauser, Tim Stearns, Vivek Philip, Beverly A Teicher, Krystal Watkins, Callum M Sloss, Patrick A Zweidler-McKay, Malcolm A Smith

Blood (2022) 140 (Supplement 1): 8983–8984.

https://doi.org/10.1182/blood-2022-159867

Published: 2022

Journal Articles

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Blood (2022) 140 (Supplement 1): 145–149.

https://doi.org/10.1182/blood-2022-158030

Published: 2022

Journal Articles

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Blood (2022) 140 (Supplement 1): 6387–6389.

https://doi.org/10.1182/blood-2022-159694

Published: 2022

Journal Articles

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 1284.

https://doi.org/10.1182/blood-2021-146666

Published: 2021

Journal Articles

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 4440.

https://doi.org/10.1182/blood-2021-146585

Published: 2021

Journal Articles

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2021) 138 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2021-146681

Published: 2021

Journal Articles

Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report

Blood (2021) 138 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2021-148593

Published: 2021

Journal Articles

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 372.

https://doi.org/10.1182/blood-2021-146503

Published: 2021

Journal Articles

Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study

Blood (2021) 138 (Supplement 1): 211.

https://doi.org/10.1182/blood-2021-147386

Published: 2021

Journal Articles

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Vinitha Mary Kuruvilla, MSc, Qi Zhang, PhD, Naval Daver, MD, Krystal Watkins, Callum M Sloss, PhD, Patrick A Zweidler-McKay, MDPhD, Angela Romanelli, PhD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136791

Published: 2020

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-139903

Published: 2020

Journal Articles

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-139081

Published: 2020

Journal Articles

A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Naval Daver, MD, Kendra L. Sweet, MD MS, Pau Montesinos, MD PhD, Eunice S. Wang, MD, Ahmed Aribi, MD, Daniel J. DeAngelo, MD PhD, Harry P Erba, MDPhD, Giovanni Martinelli, MD, Roland P Walter, MDPhD, Jessica K Altman, MD, Anjali S Advani, MD, Antonio Curti, MDPhD, Callum M Sloss, PhD, Kara E Malcolm, RN, Patrick A Zweidler-McKay, MDPhD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-139884

Published: 2020

NARROW

Preclinical Characterization of the Anti-Leukemia Activity of the CD123 Antibody-Drug Conjugate, Pivekimab Sunirine (IMGN632)

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study

Venetoclax Synergizes with IMGN632, a Novel CD123-Targeting Antibody Conjugated to a DNA Alkylating Payload, By Suppressing DNA Damage Response and Potentiating Apoptosis in Acute Myeloid Leukemia in Vitro Models

Spatial Response to Pivekimab Sunirine (IMGN632) In Vivo in a BPDCN Model

Risk-Adjusted Therapies Yield Equivalent Outcomes for Adolescents and Young Adults (AYAs) Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) on Children's Oncology Group (COG) Studies AALL0434 and AALL1231

Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children’s Oncology Group report

Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children's Oncology Group (COG) Trial AALL1231

Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report

Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia

Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study

Combining IMGN632, a Novel CD123-Targeting Antibody Drug Conjugate with Azacitidine and Venetoclax Facilitates Apoptosis in Vitro and Prolongs Survival In Vivo in AML Models

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report

A Phase 1b/2 Study of IMGN632, a CD123-Targeting Antibody-Drug Conjugate (ADC), As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only